Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
-
- Nora Liebers
- Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany;
-
- Johannes Duell
- Department of Internal Medicine II, Würzburg University Hospital, University of Würzburg, Würzburg, Germany;
-
- Donnacha Fitzgerald
- Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany;
-
- Andrea Kerkhoff
- Department of Medicine A, University Hospital Münster, Münster, Germany;
-
- Daniel Noerenberg
- Department of Hematology, Oncology and Tumor Immunology (Campus Virchow-Klinikum), Charité University Medicine, Berlin, Germany;
-
- Eva Kaebisch
- Department of Hematology, Oncology and Tumor Immunology (Campus Virchow-Klinikum), Charité University Medicine, Berlin, Germany;
-
- Fabian Acker
- Department of Medicine 2, Hematology and Oncology, University Hospital Frankfurt, Frankfurt, Germany;
-
- Stephan Fuhrmann
- Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany;
-
- Corinna Leng
- Department of Hematology, Oncology, and Tumor Immunology (Campus Benjamin Franklin), Charité University Medicine, Berlin, Germany;
-
- Manfred Welslau
- MVZ am Klinikum Aschaffenburg, Onkologie und Hämatologie, Aschaffenburg, Germany;
-
- Jens Chemnitz
- Gemeinschaftsklinikum Mittelrhein GmbH, Koblenz, Germany;
-
- Jan-Moritz Middeke
- University Hospital Dresden, Dresden, Germany;
-
- Thomas Weber
- Department of Medicine IV, Hematology and Oncology, University of Halle, Halle, Germany;
-
- Udo Holtick
- Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne, University of Cologne, Cologne, Germany;
-
- Ralf Trappe
- Department of Hematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, Bremen, Germany;
-
- Roald Pfannes
- Department of Medicine I, Städtisches Klinikum Dessau, Dessau, Germany;
-
- Ruediger Liersch
- Praxis Medical Center, Gemeinschaftspraxis für Hämatologie und Onkologie Münster, Münster, Germany;
-
- Christian Spoer
- MVZ am EVK Düsseldorf, Internistische Onkologie und Hämatologie, Düsseldorf, Germany;
-
- Stefan Fuxius
- Onkologische Schwerpunktpraxis Heidelberg, Heidelberg, Germany;
-
- Niklas Gebauer
- Department of Haematology and Oncology, University Hospital of Schleswig-Holstein, Campus Lübeck, Germany;
-
- Léandra Caillé
- Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany;
-
- Thomas Geer
- Diakonie Klinikum Schwäbisch-Hall, Innere Medizin III, Schwäbisch Hall, Germany;
-
- Christian Koenecke
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;
-
- Ulrich Keller
- Department of Hematology, Oncology, and Tumor Immunology (Campus Benjamin Franklin), Charité University Medicine, Berlin, Germany;
-
- Rainer Claus
- Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany;
-
- Dimitrios Mougiakakos
- Department of Internal Medicine 5, Hematology and Clinical Oncology, Friedrich-Alexander University (FAU) of Erlangen-Nuremberg, Erlangen, Germany;
-
- Stephanie Mayer
- Department of Internal Medicine III, University Hospital of Regensburg, Regensburg, Germany;
-
- Andreas Huettmann
- Department of Hematology, University Hospital of Essen, Essen, Germany;
-
- Christiane Pott
- Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Germany;
-
- Arne Trummer
- Department of Hematology and Oncology, Klinikum Braunschweig, Braunschweig, Germany;
-
- Gerald Wulf
- Clinic for Hematology and Medical Oncology, University Medicine Göttingen, Germany; and
-
- Uta Brunnberg
- Department of Medicine 2, Hematology and Oncology, University Hospital Frankfurt, Frankfurt, Germany;
-
- Lars Bullinger
- Department of Hematology, Oncology and Tumor Immunology (Campus Virchow-Klinikum), Charité University Medicine, Berlin, Germany;
-
- Georg Hess
- Department of Hematology, Oncology and Pneumology, Johannes Gutenberg-University, Mainz, Germany
-
- Carsten Mueller-Tidow
- Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany;
-
- Bertram Glass
- Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany;
-
- Georg Lenz
- Department of Medicine A, University Hospital Münster, Münster, Germany;
-
- Peter Dreger
- Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany;
-
- Sascha Dietrich
- Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany;
抄録
<jats:p>The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.</jats:p>
収録刊行物
-
- Blood Advances
-
Blood Advances 5 (13), 2707-2716, 2021-07-01
American Society of Hematology